1033 related articles for article (PubMed ID: 20844345)
81. [Experience with the use of palonosetron (onicit) in patients with solid tumors receiving cytostatic therapy].
Vladimirova LY; Mitashok IS; Storozhakova AE; Kalabanova EA; Svetitskaya YV; Kabanov SN
Vopr Onkol; 2015; 61(4):653-5. PubMed ID: 26571839
[TBL] [Abstract][Full Text] [Related]
82. A systematic review and meta-analysis of intravenous palonosetron in the prevention of chemotherapy-induced nausea and vomiting in adults.
Likun Z; Xiang J; Yi B; Xin D; Tao ZL
Oncologist; 2011; 16(2):207-16. PubMed ID: 21282670
[TBL] [Abstract][Full Text] [Related]
83. Recent advances and updated guidelines in the management of chemotherapy-induced nausea and vomiting.
Schwartzberg LS; Grunberg SM; Kris MG
Clin Adv Hematol Oncol; 2011 Nov; 9(11 Suppl 27):1-14; quiz 15-6. PubMed ID: 22362372
[TBL] [Abstract][Full Text] [Related]
84. Mechanisms and latest clinical studies of new NK1 receptor antagonists for chemotherapy-induced nausea and vomiting: Rolapitant and NEPA (netupitant/palonosetron).
Rojas C; Slusher BS
Cancer Treat Rev; 2015 Dec; 41(10):904-13. PubMed ID: 26442475
[TBL] [Abstract][Full Text] [Related]
85. [Efficacy of granisetron for preventing chemotherapy-induced nausea and vomiting in patients with acute myelogenous leukemia treated with a combination of anthracycline and cytarabine].
Goto T; Tanimoto K; Ishibashi M; Okamura S
Gan To Kagaku Ryoho; 2012 Aug; 39(8):1227-32. PubMed ID: 22902447
[TBL] [Abstract][Full Text] [Related]
86. Is there an association between PONV and chemotherapy-induced nausea and vomiting?
Oddby-Muhrbeck E; Öbrink E; Eksborg S; Rotstein S; Lönnqvist PA
Acta Anaesthesiol Scand; 2013 Jul; 57(6):749-53. PubMed ID: 23281590
[TBL] [Abstract][Full Text] [Related]
87. Granisetron. A pharmacoeconomic evaluation of its use in the prophylaxis of chemotherapy-induced nausea and vomiting.
Plosker GL; Benfield P
Pharmacoeconomics; 1996 Apr; 9(4):357-74. PubMed ID: 10160110
[TBL] [Abstract][Full Text] [Related]
88. Palonosetron for the treatment of chemotherapy-induced nausea and vomiting.
Navari RM
Expert Opin Pharmacother; 2014 Dec; 15(17):2599-608. PubMed ID: 25323946
[TBL] [Abstract][Full Text] [Related]
89. Pharmacogenetics of antiemetics for chemotherapy-induced nausea and vomiting: A systematic review and meta-analysis.
Eliasen A; Dalhoff K; Mathiasen R; Schmiegelow K; Rechnitzer C; Schelde AB; Perwitasari DA; Tsuji D; Brok J
Crit Rev Oncol Hematol; 2020 May; 149():102939. PubMed ID: 32259776
[TBL] [Abstract][Full Text] [Related]
90. Olanzapine for the prevention of chemotherapy-induced nausea and vomiting in patients receiving highly or moderately emetogenic chemotherapy: a randomized, double-blind, placebo-controlled study.
Mizukami N; Yamauchi M; Koike K; Watanabe A; Ichihara K; Masumori N; Yamakage M
J Pain Symptom Manage; 2014 Mar; 47(3):542-50. PubMed ID: 23856100
[TBL] [Abstract][Full Text] [Related]
91. Review of the preclinical pharmacology and comparative efficacy of 5-hydroxytryptamine-3 receptor antagonists for chemotherapy-induced emesis.
Perez EA
J Clin Oncol; 1995 Apr; 13(4):1036-43. PubMed ID: 7707101
[TBL] [Abstract][Full Text] [Related]
92. Granisetron Extended-Release Injection: A Review in Chemotherapy-Induced Nausea and Vomiting.
Deeks ED
Drugs; 2016 Dec; 76(18):1779-1786. PubMed ID: 27915445
[TBL] [Abstract][Full Text] [Related]
93. Evaluation of the acute effect of palonosetron on transmural dispersion of myocardial repolarization.
Dogan U; Yavas G; Tekinalp M; Yavas C; Ata OY; Ozdemir K
Eur Rev Med Pharmacol Sci; 2012 Apr; 16(4):462-8. PubMed ID: 22696873
[TBL] [Abstract][Full Text] [Related]
94. Slow-release granisetron (APF530) versus palonosetron for chemotherapy-induced nausea/vomiting: analysis by American Society of Clinical Oncology emetogenicity criteria.
Raftopoulos H; Boccia R; Cooper W; O'Boyle E; Gralla RJ
Future Oncol; 2015 Sep; 11(18):2541-51. PubMed ID: 26289588
[TBL] [Abstract][Full Text] [Related]
95. New and emerging therapeutic options for the management of chemotherapy-induced nausea and vomiting.
Schwartzberg LS; Rugo HS; Aapro MS
Clin Adv Hematol Oncol; 2015 Mar; 13(3 Suppl 3):3-13, 1; quiz 2 p following 14. PubMed ID: 25856052
[TBL] [Abstract][Full Text] [Related]
96. WITHDRAWN: Serotonin receptor antagonists for highly emetogenic chemotherapy in adults.
Billio A; Morello E; Clarke MJ
Cochrane Database Syst Rev; 2013 Dec; 2013(12):CD006272. PubMed ID: 24323437
[TBL] [Abstract][Full Text] [Related]
97. Antiemetic Prophylaxis for Chemotherapy-Induced Nausea and Vomiting.
Navari RM; Aapro M
N Engl J Med; 2016 Apr; 374(14):1356-67. PubMed ID: 27050207
[No Abstract] [Full Text] [Related]
98. Tropisetron: an update of its use in the prevention of chemotherapy-induced nausea and vomiting.
Simpson K; Spencer CM; McClellan KJ
Drugs; 2000 Jun; 59(6):1297-315. PubMed ID: 10882164
[TBL] [Abstract][Full Text] [Related]
99. 5HT3-receptor antagonists as antiemetics in cancer.
Drug Ther Bull; 2005 Aug; 43(8):57-62. PubMed ID: 16111085
[TBL] [Abstract][Full Text] [Related]
100. Delayed emesis: moderately emetogenic chemotherapy (single-day chemotherapy regimens only).
Roila F; Warr D; Aapro M; Clark-Snow RA; Einhorn L; Gralla RJ; Herrstedt J; Saito M; Tonato M
Support Care Cancer; 2011 Mar; 19 Suppl 1():S57-62. PubMed ID: 21132332
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
